Venetoclax and blinatumomab based chemotherapy-free treatment in a patient with Philadelphia chromosome-negative acute lymphoblastic leukemia

Ann Hematol. 2023 May;102(5):1275-1277. doi: 10.1007/s00277-023-05127-3. Epub 2023 Mar 9.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Bispecific* / therapeutic use
  • Antineoplastic Agents* / therapeutic use
  • Humans
  • Philadelphia Chromosome
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma* / drug therapy
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma* / genetics
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma* / drug therapy
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma* / genetics

Substances

  • blinatumomab
  • venetoclax
  • Antineoplastic Agents
  • Antibodies, Bispecific